Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onconova initiates Phase I study of radioprotective drug
The Phase I clinical trial was initiated to evaluate the safety, tolerability and pharmacokinetics of ON 01210.Na in healthy volunteers. Data from this initial trial will be used
The Phase I clinical trial was initiated to evaluate the safety, tolerability and pharmacokinetics of ON 01210.Na in healthy volunteers. Data from this initial trial will be used
The board also announced that it has commenced a search for a permanent replacement for departing president and CEO, Arie Cohen, who has left the company to pursue
Renamed Rem Medical Clinical Research, the new clinical research division is working closely with pharmaceutical companies and their contract research organizations to provide Phase II-IV trial services to
Telavancin is a bactericidal, once-daily injectable investigational antibiotic with a multifunctional mechanism of action. Telavancin was discovered by Theravance in a research program dedicated to finding new antibiotics
Prior to joining Aragon Surgical, Mr Snow served as director of sales and marketing at Medlogics, a cardiology device company. Prior to Medlogics, Mr Snow served at Rubicor
AstraZeneca markets Prilosec for the treatment of duodenal/gastric ulcers and gastro-esophageal reflux disease. The company’s versions of generic Prilosec (including previously approved and marketed 10mg and 20mg capsules)
This patent, exclusively licensed from the Massachusetts General Hospital, provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture. Kundakovic, president of FluoroPharma,
Adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, was $1.06 for the fourth quarter of 2008, an increase of 6% compared to $1
According to the company, the clearance enables it to move forward with the world’s first study of a human embryonic stem cell (hESC)-based therapy in man. Geron plans
Under the collaboration, Corgenix will work with Battelle on biodefense related projects and programs. Under the terms of the collaboration agreement, Corgenix will provide biodefense project support to